Señales en vivo de SLRN | Maximiza tus Ganancias con Getagraph.com

COMPRAR 137148 min ago

@ $7.58

Emitido: 14 feb 2024 @ 10:18

Retorno: -42.08%

Señal anterior: feb 13 - 12:30

Señal anterior: Vender

Retorno: -1.69 %

Live Chart Being Loaded With Signals

Commentary (17 may 2024 @ 16:00):

Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines...

Stats
Volumen de hoy	738 410
Volumen promedio	1.19M
Capitalización de mercado	434.73M
EPS	$0 ( 2024-05-13 )
Próxima fecha de ganancias	( $-0.930 ) 2024-08-12
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.810
ATR14	$0.00800 (0.18%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-09	Lin Shao-lee	Buy	964 829	Employee Stock Option (right to buy)
2024-01-09	Lin Shao-lee	Buy	413 498	Employee Stock Option (right to buy)
2024-01-09	Labrucherie Gil M	Buy	855 513	Employee Stock Option (right to buy)
2024-01-02	Lin Shao-lee	Sell	10 691	Common Stock
2023-12-18	Tetrault Lynn A.	Buy	89 955	Director Stock Option (right to buy)

INSIDER POWER
-1.26
Last 57 transactions
Buy: 28 627 675 \| Sell: 30 925 812

Volumen Correlación

Largo: -0.14 (neutral)

Corto: -0.58 (weak negative)

Signal:(50.492) Neutral

Acelyrin, Inc. Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Acelyrin, Inc. Correlación - Moneda/Commodity

0.33
( neutral )

0.34
( neutral )

0.00
( neutral )

0.58
( weak )

0.00
( neutral )

0.31
( neutral )

Acelyrin, Inc. Finanzas

Annual	2023
Ingresos:	$0
Beneficio Bruto:	$0 (0.00 %)
EPS:	$-5.43

FY	2023
Ingresos:	$0
Beneficio Bruto:	$0 (0.00 %)
EPS:	$-5.43

FY	2022
Ingresos:	$0
Beneficio Bruto:	$0 (0.00 %)
EPS:	$-12.25

Financial Reports:

No articles found.

Acelyrin, Inc. Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Acelyrin, Inc.

Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody against insulin-like growth factor 1 receptor, which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease; and SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria. The company was incorporated in 2020 and is headquartered in Agoura Hills, California.